Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
KOD 
Kodiak Sciences Inc (KOD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/27/2025: KOD (3-star) is a WEAK-BUY. BUY since 40 days. Profits (-17.59%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Year Target Price $6.8
Year Target Price $6.8
| 1 | Strong Buy |
| 0 | Buy |
| 2 | Hold |
| 0 | Under performing |
| 3 | Sell |
Analysis of Past Performance
Type Stock | Historic Profit 191.15% | Avg. Invested days 41 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 06/27/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 195.22M USD | Price to earnings Ratio - | 1Y Target Price 6.8 |
Price to earnings Ratio - | 1Y Target Price 6.8 | ||
Volume (30-day avg) - | Beta 2.28 | 52 Weeks Range 1.92 - 11.60 | Updated Date 06/29/2025 |
52 Weeks Range 1.92 - 11.60 | Updated Date 06/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -3.62 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -34.1% | Return on Equity (TTM) -108.92% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 123485466 | Price to Sales(TTM) - |
Enterprise Value 123485466 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.12 | Shares Outstanding 52763500 | Shares Floating 32344470 |
Shares Outstanding 52763500 | Shares Floating 32344470 | ||
Percent Insiders 5.52 | Percent Institutions 81.78 |
Analyst Ratings
Rating 2.83 | Target Price 6.8 | Buy - | Strong Buy 1 |
Buy - | Strong Buy 1 | ||
Hold 2 | Sell 3 | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Kodiak Sciences Inc
Company Overview
History and Background
Kodiak Sciences Inc. is a biopharmaceutical company founded in 2006. It focuses on developing novel therapeutics to treat high-prevalence retinal diseases. Key milestones include the development of the Antibody Biopolymer Conjugate (ABC) platform and the progression of tarcocimab tedromer through clinical trials.
Core Business Areas
- Retinal Disease Therapeutics: Development and commercialization of novel therapies for retinal diseases, including age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion (RVO).
Leadership and Structure
Victor Perlroth is the current CEO. The company has a typical biopharmaceutical structure with departments focused on research, clinical development, manufacturing, and commercialization.
Top Products and Market Share
Key Offerings
- Tarcocimab Tedromer: Kodiak's lead product candidate, an anti-VEGF ABC conjugate designed to improve durability and reduce treatment frequency for retinal diseases. Currently in clinical trials, it has no market share yet. Competitors include Eylea (REGN), Lucentis (LLY), Beovu (NVS) and Vabysmo (RHHBY).
Market Dynamics
Industry Overview
The retinal disease therapeutics market is large and growing, driven by an aging population and increasing prevalence of diabetes. The market is dominated by anti-VEGF therapies, but there is a need for more durable and convenient treatments.
Positioning
Kodiak Sciences aims to disrupt the retinal disease market with its ABC platform, offering the potential for longer-lasting treatments and reduced injection frequency. Their success hinges on positive clinical trial outcomes for Tarcocimab Tedromer.
Total Addressable Market (TAM)
The global retinal disease treatment market is projected to reach $15.6 billion by 2027. Kodiak Sciences is positioned to capture a portion of this market if Tarcocimab Tedromer proves successful and is approved.
Upturn SWOT Analysis
Strengths
- Novel ABC platform technology
- Potential for extended durability in retinal disease treatment
- Experienced leadership team
- Strong intellectual property position
Weaknesses
- Reliance on single lead product candidate
- Clinical trial risk
- No currently marketed products
- High cash burn rate
Opportunities
- Partnerships with larger pharmaceutical companies
- Expansion into other retinal disease indications
- Potential for premium pricing due to improved durability
- Positive clinical trial results leading to regulatory approval
Threats
- Competition from established anti-VEGF therapies
- Clinical trial failures
- Regulatory hurdles
- Generic entry of existing anti-VEGF drugs
Competitors and Market Share
Key Competitors
- REGN
- LLY
- NVS
- RHHBY
Competitive Landscape
Kodiak Sciences competes with established pharmaceutical companies that have marketed anti-VEGF therapies for retinal diseases. Its success depends on demonstrating superior efficacy and durability with tarcocimab tedromer.
Growth Trajectory and Initiatives
Historical Growth: Kodiak Sciences' growth has been driven by the advancement of its ABC platform and the progression of tarcocimab tedromer through clinical trials.
Future Projections: Future growth depends on the success of tarcocimab tedromer and other pipeline candidates. Analyst estimates vary depending on the perceived probability of success.
Recent Initiatives: Recent initiatives include enrolling patients in ongoing clinical trials for tarcocimab tedromer and expanding its research and development efforts.
Summary
Kodiak Sciences is a high-risk, high-reward biopharmaceutical company. Its success hinges on positive clinical trial outcomes for tarcocimab tedromer. The company needs to carefully manage its cash burn rate and secure funding to support its clinical development programs. Competition from established players remains a key challenge.
Peer Comparison
Sources and Disclaimers
Data Sources:
- SEC Filings
- Company Website
- Analyst Reports
- Yahoo Finance
- Google Finance
Disclaimers:
This analysis is for informational purposes only and does not constitute investment advice. The data is based on publicly available information and may not be entirely accurate or complete. Investing in biopharmaceutical companies involves significant risks, including clinical trial failures, regulatory setbacks, and competition from other companies. Do your own research.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Kodiak Sciences Inc
Exchange NASDAQ | Headquaters Palo Alto, CA, United States | ||
IPO Launch date 2018-10-04 | Co-Founder, Chairman, CEO & President Dr. Victor Perlroth M.D. | ||
Sector Healthcare | Industry Biotechnology | Full time employees 113 | Website https://kodiak.com |
Full time employees 113 | Website https://kodiak.com | ||
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutics to treat retinal diseases. Its lead product candidate is tarcocimab tedromer (KSI-301), an anti-vascular endothelial growth factor (VEGF) antibody biopolymer that has complete Phase 3 clinical study to treat high prevalence retinal vascular diseases; and in Phase 3 clinical study for the treatment of diabetic retinopathy, wet age-related macular degeneration (AMD), retinal vein occlusion, and diabetic macular edema, as well as in Phase 2/3 clinical study to treat wet AMD. The company's preclinical stage product candidate includes KSI-501, an anti- interleukin-6 (IL-6) and VEGF-trap bispecific antibody biopolymer conjugate for high prevalence retinal vascular diseases; and KSI-101 (KSI-501P), an unconjugated bispecific protein targeting IL-6 and VEGF developed for patients who have retinal fluid and inflammation. The company was formerly known as Oligasis, LLC and changed its name to Kodiak Sciences Inc. in September 2015. Kodiak Sciences Inc. was incorporated in 2009 and is based in Palo Alto, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.